Characterization of VIP receptor-effector system antagonists in rat and mouse peritoneal macrophages

European Journal of Pharmacology

Volumn 321, Issue 3, 1997, Pages 379-386

  Pozo, David ^a   Montilla, Manuel L ^a   Guerrero, Juan M ^a   Calvo, Juan R ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Adenylyl cyclase; Isoproterenol; Neuroimmunobiology; Peritoneal macrophage; Propranolol; VIP (vasoactive intestinal peptide); VIP receptor; VIP receptor antagonist

Indexed keywords

ADENYLATE CYCLASE; CYCLIC AMP; GROWTH HORMONE RELEASING FACTOR DERIVATIVE; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE ANTAGONIST; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; COMPETITION; CONTROLLED STUDY; DRUG COMPARISON; ENZYME ACTIVITY; IN VITRO STUDY; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; RAT;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BINDING, COMPETITIVE; CELL MEMBRANE; CROSS-LINKING REAGENTS; CYCLIC AMP; ISOPROTERENOL; MACROPHAGES, PERITONEAL; MICE; PROPRANOLOL; RATS; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; SERMORELIN; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0031049374     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(96)00966-1     Document Type: Article

References (48)

1. 2: an inhibitor of vasodilation in the feline colon, Am. J. Physiol. 259, G252.
2. Bissonnette, B.M., M.J. Collen, H. Adachi, R.T. Jensen and J.D. Gardner, 1984, Receptors for vasoactive intestinal peptide and secretin on rat pancreatic acini, Am. J. Physiol. 246, G710.
3. Bradford, M.A., 1976, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding, Anal. Biochem. 72, 248.
4. Calvo, J.R., J.M. Guerrero, P. Molinero, R. Blasco and R. Goberna, 1986a, Interaction of vasoactive intestinal peptide (VIP) with human peripheral blood lymphocytes: specific binding and cyclic AMP production, Gen. Pharmacol. 17, 185.
5. Calvo, J.R., P. Molinero, J. Jimenez, R. Goberna and J.M. Guerrero, 1986b, Interaction of vasoactive intestinal peptide (VIP) with rat lymphoid cells, Peptides 7, 177.
6. Calvo, J.R., J.M. Guerrero, M.A. Lopez-Gonzalez, C. Osuna and J.J. Segura, 1994a, Characteristics of receptors for VIP in rat peritoneal macrophage membranes, Peptides 15, 309.
7. Calvo, J.R., M.L. Montilla, J.M. Guerrero and J.J. Segura, 1994b, Expression of VIP receptors in mouse peritoneal macrophages: functional and molecular characterization, J. Neuroimmunol. 50, 85.
8. Calvo, J.R., D. Pozo and J.M. Guerrero, 1996, Functional and molecular characterization of VIP receptors and signal transduction in human and rodent immune systems, Adv. Neuroimmunol. 6, 39.
9. Couvineau, A., M. Rousset and M. Laburthe, 1985, Molecular identification and structural requirement of vasoactive intestinal peptide (VIP) receptors in the human colon adenocarcinoma cell line, HT 29, Biochem. J. 231, 139.
10. Cox, H.M. and A.W. Cuthbert, 1989, Secretory actions of vasoactive intestinal polypeptide, peptide histidine isoleucine and helodermin in rat small intestine: the effects of putative VIP antagonists upon VIP-induced ion secretion, Regul. Pept. 26, 127.
11. De La Fuente, M., M. Delgado and R.P. Gomariz, 1996, VIP modulation of immune cell functions, Adv. Neuroimmunol. 6, 1.
12. Espat, N.J., G. Cheng, M.C. Kelley, S.B. Vogel, C.A. Sninsky and M.P. Hocking, 1995, Vasoactive intestinal peptide and substance P receptor antagonists improve postoperative ileus, J. Surg. Res. 58, 719.
13. Fishbein, V.A., D.H. Coy, S.J. Hocart, N.Y. Jiang, J.E. Mrozinski, S.A. Mantey and R.T. Jensen, 1994, A chimeric VIP-PACAP analogue but not VIP pseudopeptides function as VIP receptor antagonists, Peptides 15, 95.
14. Furchgott, R., 1967, The pharmacological differentiation of adrenergic receptors, Ann. NY Acad. Sci. 139, 553.
15. Gozes, I., S.K. McCune, L. Jacobson, D. Warren, T.W. Moody, M. Fridkin and D.E. Brenneman, 1991, An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system, J. Pharmacol. Exp. Ther. 257, 959.
16. Grider, J.R. and J.R. Rivier, 1990, Vasoactive intestinal peptide (VIP) as transmitter of inhibitory motor neurons of the gut: evidence from the use of selective VIP antagonists and VIP antiserum, J. Pharmacol. Exp. Ther. 253, 738.
17. 17)VIP, Pflügers Arch. 414, 222.
18. Guerrero, J.M., J.C. Prieto, F.L. Elorza, R. Ramirez and R. Goberna, 1981, Interaction of vasoactive intestinal peptide with human blood mononuclear cells, Mol. Cell. Endocrinol. 21, 151.
19. Hill, M.R.S., D.W. Wallick, L.R. Mongeon, P.J. Martin and M.N. Levy, 1995, Vasoactive intestinal polypeptide antagonists attenuate vagally induced tachycardia in the anesthetized dog, Am. J. Physiol. 38, H1467.
20. Laburthe, M., A. Couvineau and C. Rouyer-Fessard, 1986, Study of species specificity in growth hormone-releasing factor (GRF) interaction with vasoactive intestinal peptide (VIP) receptors using GRF and intestinal VIP receptors from rat and human: evidence that Ac-Tyr1 hGRF is a competitive VIP antagonist in the rat, Mol. Pharmacol. 29, 23.
21. Laemmli, U.K., 1970, Cleavage of structural proteins during the assembly of the head of bacteriophage T4, Nature 227, 680.
22. Leroux, F., J.F. Goossens, N. Pommery and J.P. Hénichart, 1994, A new vasoactive intestinal peptide antagonist discriminates VIP receptors on guinea pig trachea and human neuroblastoma cells, Regul. Pept. 52, 119.
23. Lilling, G., Y, Wollman, M.N. Goldstein, S. Rubinraut, M. Fridkin, D.E. Brenneman and I. Gozes, 1995, Inhibition of human neuroblastoma growth by a specific VIP antagonist, J. Mol. Neurosci. 5, 231.
24. Munson, P.J. and D. Rodbard, 1980, LIGAND: a versatile computerized approach for characterization of ligand-binding systems, Anal. Biochem. 107, 220.
25. 2-terminal histidyl residue, Mol. Cell Endocrinol. 52, 97.
26. O'Dorisio, M.S., N.S. Hermina, T.M. O'Dorisio and P. Balcerzak, 1981, Vasoactive intestinal polypeptide modulation of lymphocyte adenylate cyclase, J. Immunol. 127, 2551.
27. Ottaway, C.A., 1991, Vasoactive intestinal peptide and immune function, in: Psychoneuroimmunology, 2nd edn., eds. R. Ader, N. Cohen and D. Felten (Academic Press, New York, NY) p. 225.
28. Ottaway, C.A., 1992, Role of sulfhydryl groups in the binding of vasoactive intestinal peptide to its receptors on murine lymphocytes, J. Neuroimmunol. 39, 49.
29. Ottaway, C.A., C. Bernaerts, B. Chan and G.R. Greenberg, 1983, Specific binding of vasoactive intestinal peptide to human circulating mononuclear cells, Can. J. Physiol. Pharmacol. 61, 664.
30. Ottaway, C.A., T.E. Lay and G.R. Greenberg, 1990, High affinity specific binding of vasoactive intestinal peptide to human circulating T cells, B cells and large granular lymphocytes, J. Neuroimmnunol. 29, 149.
31. 17]VIP, Am. J. Physiol. 250, G553.
32. Pozo, D., J.J. Segura, I. Carrero, L.G. Guijarro, J.C. Prieto and J.R. Calvo, 1996, Characterization of adenylyl cyclase stimulated by VIP in rat and mouse peritoneal macrophage membranes, Biochim. Biophys. Acta 1312, 249.
33. 1 modifications on the ability of vasoactive intestinal peptide to stimulate adenylate cyclase from rat and human tissues, Peptides 5, 877.
34. Rodríguez-Pena, M.S., L.G. Guijarro and J.C. Prieto, 1991, Vasoactive intestinal peptide receptor anatagonists in rat seminal vesicle membranes, Eur. J. Pharmacol. 208, 207.
35. Said, S.I., 1991, Vasoactive intestinal polypeptide. Biological role in health and disease, Trends Endocrinol. Metab. 2, 107.
36. Said, S.I. and V. Mutt, 1970, Polypeptide with broad activity: isolation from small intestine, Science 169, 1217.
37. Scatchard, G., 1949, The attractions of proteins for small molecules and ions, Ann. NY Acad. Sci. 51, 660.
38. Segura, J.J., J.M. Guerrero, R. Goberna and J.R. Calvo, 1991, Characterization of functional receptors for vasoactive intestinal peptide (VIP) in rat peritoneal macrophages, Regul. Pept. 35, 133.
39. Segura, J.J., J.M. Guerrero, R. Goberna and J.R. Calvo, 1992a, Stimulatory effect of vasoactive intestinal peptide (VIP) on cyclic AMP production in rat peritoneal macrophages, Regul. Pept. 37, 195.
40. Segura, J.J., J.M. Guerrero, R. Goberna and J.R. Calvo, 1992b, Guanine nucleotide regulation of VIP binding to rat peritoneal macrophage membranes, Peptides 13, 953.
41. Segura, J.J., J.M. Guerrero, M.A. Lopez-Gonzalez and J.R. Calvo, 1993, Vasoactive intestinal peptide (VIP) inhibits substrate adherence capacity of rat peritoneal macrophages by a mechanism that involves cAMP, Cell Adh. Commun. 1, 213.
42. Sirianni, M.C., B. Annibale, F. Tagliaferri, S. Fais, S. De Luca, F. Pallone, G. Delle Fave and F. Aiutti, 1992, Modulation of human natural killer activity by vasoactive intestinal peptide (VIP) family. VIP, glucagon and GHRF specifically inhibit NK activity, Regul. Pept. 38, 79.
43. Tseng, J. and M.S. O'Dorisio, 1989, Mechanism of vasoactive intestinal peptide (VIP)-mediated immunoregulation, in: Neuroimmune Networks: Physiology and Diseases, eds. E.S. Goetzl and N.H. Spector (R.L. Alan, New York, NY) p. 105.
44. Turner, J.T., S.B. Jones and D.B. Bylund, 1986, A fragment of vasoactive intestinal peptide, VIP (10-28), is an antagonist of VIP in the colon carcinoma cell line, HT29, Peptides 7, 849.
45. 2 as a VIP anatagonist, Endocrinology 116, 2643.
46. 2, J. Immunol. 154, 1909.
47. Wiik, P., P.K. Opstad and A. Boyum, 1985, Binding of vasoactive intestinal polypeptide (VIP) by human blood monocytes: demonstration of specific binding sites, Regul. Pept. 12, 145.
48. 2)-GRF-(1-29), specifically antagonizes the facilitation of the flexor reflex induced by intrathecal vasoactive intestinal peptide in rat spinal cord, Neuropeptides 18, 129.